

## Cuvitru

Saudi Arabia · access guide

# How to access Cuvitru for primary immunodeficiency from Saudi Arabia: 2026 pathway via KFSHRC and KAMC allergy-immunology | Reserve Meds

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Saudi Arabia diagnoses and manages primary immunodeficiency (PI) patients through allergy-immunology services at KFSHRC Riyadh, KAMC Riyadh and Jeddah, and KFMC. The longstanding domestic IVIG programme is mature. The 2026 question for selected adults and paediatric patients aged 2 and older is whether to convert from monthly IVIG cycle to weekly self-administered subcutaneous Cuvitru and how to source it under SFDA.

## Why Cuvitru, why now

Cuvitru is a subcutaneous immune globulin (human) 20% formulation labelled for primary humoral immunodeficiency in adults and paediatric patients aged 2 and older. It is self-administered weekly after training. For patients with venous access difficulty, IVIG-cycle wear-off symptoms, or those who travel and cannot anchor monthly infusion clinic visits, SC IgG meaningfully changes quality of life.

Reserve Meds does not promote one IgG product over another. Other IgG choices for the same indication include Hyqvia (hyaluronidase-facilitated SC), Octagam, Gammagard, Privigen, and Cuvitru; the choice rests with the treating allergist-immunologist.

## What Cuvitru is, in plain language

Cuvitru is a 20% liquid IgG product injected under the skin (subcutaneous) at the abdomen or thigh, once weekly (or more frequent split dosing). Most patients self-administer at home after a training programme. Pump-driven over 60-90 minutes per session. Steady-state IgG trough is reached after several weeks.

## Eligibility at a Saudi allergy-immunology clinic

Required: confirmed PI diagnosis with documented IgG deficiency and impaired specific antibody response or genetic confirmation. Patient or caregiver willing and able to learn SC self-administration. Reasonable IgG trough goal already established (typically 5-7 g/L or higher for pneumonia history).

## The Saudi prescribing and supply picture

---

Cuvitru is not currently listed as SFDA-registered. Access is via SFDA named-patient personal-import or via institutional special-access through KFSHRC, KAMC, or KFMC pharmacy. Cold-chain storage required (2 to 8 degrees C). Reserve Meds coordinates the import file, prescription chain, and shipping.

## Cost band

---

USD 75K-110K annual per patient (SAR 280K-415K), weight-and-dose dependent. MoH and Council of Health Insurance rare-disease provision may cover for confirmed PI cases case-by-case; private insurance often covers IVIG/SCIG but pre-authorisation is required.

## What to expect, week-by-week

---

Weeks 0 to 2: SFDA import filing, prescription, training arrangement. Weeks 2 to 4: shipment arrives, in-clinic supervised SC training over 2-3 sessions until self-administration is confident. Weeks 4 to 16: weekly SC at home; IgG trough check at week 12. Month 6 and 12: full reassessment, infection-event log review, dose adjustment.

## When Cuvitru is the wrong drug

---

If venous access is fine and the patient does not want to self-inject, IVIG is more appropriate. If the patient cannot reliably self-administer, IVIG monthly is safer. If steady-state IgG trough has been hard to achieve on weekly SC, larger less-frequent SC dosing may be considered. Reserve Meds does not promote one IgG product over another; the choice is the allergist-immunologist's.

## Closing

---

Reserve Meds runs the Cuvitru import file from the KFSHRC, KAMC, or KFMC allergy-immunology referral through SFDA named-patient authorisation and delivered cold-chain supply. Clinical decisions remain with your treating allergist-immunologist.

### *Reserve Meds's role*

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### Reserve Meds

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com